Case Study

Biomarkers for the Early Stages of Heart Failure

Early targeting of specific metabolites may offer a novel approach to preventing heart failure in patients with hypertension-induced left ventricular hypertrophy.

This study provides a comprehensive metabolite analysis of a rodent model of hypertension, offering insights into the changes in cardiac energy metabolism early in hypertension development. The early detection of metabolic abnormalities could serve as biomarkers for hypertension-induced left ventricular hypertrophy.

Talk With An Expert About Your Project

Biomarkers for the Early Stages of Heart Failure

The Challenge: Understanding the Early Stages of Heart Failure

Cardiovascular disease (CVD) continues to be the leading cause of death worldwide, despite significant advances in the treatment of CVD. A major contributor to these deaths is high blood pressure (hypertension). Chronic hypertension leads to left ventricular hypertrophy (LVH) and, eventually, heart failure (HF). HF has been linked to high morbidity and mortality rates, with 1-year mortality rates as high as 22%. Early detection and prevention of LVH are thus essential; however, more mechanistic studies are needed to understand the early stages of HF. The spontaneously hypertensive rat (SHR) is the most studied animal model of hypertension and is used to study cardiovascular disease progression. SHRs are widely used to examine the transition from LVH to HF because their slow progression to HF mimics human disease. LVH and HF have been linked to metabolic abnormalities. Metabolomics offers a unique opportunity to identify perturbations in heart metabolism before and during the development of LVH and to create treatment strategies to prevent LVH.

Metabolon Insight: Unraveling Metabolic Mechanisms Related to Heart Failure

This study utilized the Metabolon Global Discovery Panel to profile the hearts of SHRs and control rats.¹ The goal was to compare the metabolomic profiles of SHRs during early hypertension development to control rats. The Global Discovery Panel has unrivaled coverage of over 5,400 semi-quantifiable analytes and offered this research group the most comprehensive solution for comparing the metabolomic profiles of SHRs during early hypertension development to control rats. This provided a foundation of knowledge for elucidating common traits and relationships between SHR cohorts compared to their control group.

The Solution: Metabolomics Assesses Metabolic Changes Associated with Hypertension Development

To assess metabolic changes in SHR hearts, the research team performed an untargeted metabolomic analysis of SHR and control hearts at two months of age. Data analysis revealed significant differences in several energy-providing metabolic pathways, such as fatty acid, glucose, and branched-chain amino acid (BCAA) metabolism. Most remarkably, fatty acyl-carnitines, all BCAAs (leucine, isoleucine, and valine), BCAA-derived carnitines, and a few long-chain free fatty acids were increased. Increased levels of lactate and pyruvate and decreased dihydroxyacetone phosphate levels reflected changes in glucose metabolism. Metabolites within the glycogen breakdown pathway were significantly reduced, while aldose reductase/polyol pathway products increased. Several nucleotide metabolites, such as purine and pyrimidine, were significantly decreased in SHR hearts, but others, such as adenosine monophosphate (AMP), adenosine diphosphate (ADP), and dihydroorotate were elevated.

Oxidative stress in SHR hearts was determined via substantial increases in lipid oxidation and peroxidation products (monohydroxy fatty acids, fatty acid dicarboxylates, oxidized fatty acid 4-hydroxy-2-noneal, eicosanoids, 7-hydroxycholesterol, and endocannabinoids). Three amino acids necessary for glutathione synthesis were decreased. Other remarkable lipid abnormalities in SHR hearts were changes in diacylglycerols, membrane phospholipids, sphingolipids, and ceramide levels.

The Outcome: Novel Biomarkers for the Early Detection of Heart Failure

This study provides a comprehensive metabolite analysis of SHR hearts, offering insights into the changes in cardiac energy metabolism early in hypertension development. The early detection of metabolic abnormalities related to hypertension-induced LVH could allow for earlier detection and treatment of this medical condition and may offer a novel approach to preventing HF in patients with hypertension-induced LVH.

References

1. Li J, Kemp BA, Howell NL, et al. Metabolic Changes in Spontaneously Hypertensive Rat Hearts Precede Cardiac Dysfunction and Left Ventricular Hypertrophy. J Am Heart Assoc. Feb 19 2019;8(4):e010926. doi:10.1161/JAHA.118.010926

Related Case Studies

See All Case Studies

Metabolomics finds PanK4 to be an Important Regulator of Glucose Uptake and Lipid Metabolism

Find out more $

Metabolomics provides insight into the pathology of sudden infant death syndrome and identifies biomarker candidates

Find out more $

Metabolomics Reveals Beneficial Changes to Metabolite Profiles During Diabetes Remission

Find out more $

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.